Adherence to Oral Anticancer Treatment, Drug Related Toxicity, Multidisciplinary Consultation Program, Securing Medication Management
Conditions
Keywords
Multidisciplinary consultation program, adherence to oral anticancer treatment, drug related toxicity, securing medication management
Brief summary
Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications. The movement to oral oncology medications has altered the balance of risks and adverse effects (AEs) in the treatment of cancer care. These treatments are associated with a different constellation of AEs and drug interactions. Patients receiving treatment with oral anticancer treatment (OAT) encounter several barriers to adherence, which may include limited access to specialty medications, severe adverse effects, complex medication regimens, and special handling precautions. Medication nonadherence not only reduces the efficacy of drug therapy but also has the potential to increase healthcare expenditures due to disease-related hospitalizations. The purpose of this study is to evaluate the drug adherence in cancer patients, using the medication possession ratio (MPR), before and after the implementation of a multidisciplinary consultation program (MCP), on initiation of OAT.
Interventions
DEVICEmultidisciplinary consultation program
The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* French speaking patients with a newly diagnosed or relapsed cancer, regardless of location and introduction of oral anticancer treatment
Exclusion criteria
* patients treated with hormone therapy only * Patient with severe psychiatric disorders * patient who does not speak the French language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| medication possession ratio (MPR) | two months | The MPR makes it possible to determine the percentage of days of treatment covered by pharmacy dispensing. A patient is generally considered observant if MPR is greater than or equal to 80%. |
Countries
France
Contacts
Primary ContactAurélie terrier-lenglet, DR
Outcome results
None listed